For more information on Pharmacyclics LLC, an AbbVie Company please visit Pharmacyclics.com
Benchmarking is a powerful way to understand how your practice is doing compared to other oncology practices nationwide. You will see where you are succeeding and also where there may be opportunities for improvement. Is your staffing level higher than most other practices? Are there ways you can improve revenue cycle management ? Can you see more patients? How do your operating expenses compare with others?
These questions can be answered by utilizing the power of COAnalyzer and the continual stream of learning and information sharing. Throughout the year, COA will provide newsletters and webinars to supplement the information contained in COAnalyzer and give you more indepth insights for running your practice.
CPAN was created in recognition of the vital role patients should play in advocating for access to local affordable care for all cancer patients. CPAN complements the work of COA, which has established a record of unprecedented success in mobilizing community oncology to raise awareness of the issues facing cancer care delivery and to become politically active.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.
Contact
Camarie King
Field Reimbursement Manager
cking@gene.com
410-402-3049
AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day, eliminate cancer as a cause of death.
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative firsts, Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, urology and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.
Rooted in rich scientific collaborations and community-based relationships, we have access to some of the top minds in science today, allowing us to advance the treatment of patients through our innovative medicines. Our discoveries lead us not only to new treatments, but also to new ways to empower patients and expand their access to quality care. For more about Janssen Biotech, Inc., visit www.janssenbiotech.com.
Seattle Genetics is a global biotechnology company that discovers, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. For more information, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter
NeoGenomics is leading cancer reference laboratory serving oncologists and pathologists. A Lab Collaboration with NeoGenomics is a business collaboration working with a dedicated team to help customize a long-term, multi-phase laboratory internalization strategy. We provide extensive turn-key services to evaluate and identify the appropriate lab methodologies for internalization, assist in the unification of your reference lab solutions and aid in your ability to optimize patient care.
Community-based oncologists rely on ION Solutions for creative GPO contracting, integrated dispensing solutions, and the expertise practices need to improve clinical and operational management. Pharmaceutical manufacturers rely on us as a trusted preferred partner for achieving product exposure and driving growth with existing products. Managed care companies depend on us to develop innovative programs to reduce overall costs and variability of care among our practices.
With our extensive industry network experience, we have the knowledge, consulting guidance, and contracting programs to help oncology practices succeed.
In 1998, we partnered with Oncology Supply as our exclusive distributor. For over 35 years, they have distributed chemotherapy and supportive care products to independent oncology practices nationwide.
Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.
Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ more than 1,400 people and have operations in the U.S., Europe and Japan.
Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit www.flatiron.com or follow us @FlatironHealth
Cardinal Health Specialty Solutions and VitalSource™ GPO empower community oncology practices to navigate the future of oncology care. Working in close collaboration with each practice, we develop and implement a clear roadmap to meet pressing challenges in a new era. With expert insights, responsive tools and committed support, we enable our customers to deliver high-quality, cost-efficient care and future-proof their practices.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular and neuroscience.
Through the Bristol Myers Squibb Foundation, an independent 501(c)(3) charitable organization, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Our employees around the world work every day to transform patients’ lives through science.
Astellas Pharma US, Inc is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world.
Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. Since 2007, Sanofi & Regeneron have collaborated to develop & commercialize fully human monoclonal antibodies utilizing proprietary technologies.
Walgreens is focused on expert cancer care. Our pharmacists and pharmacy technicians, who have advanced cancer training and expertise, go beyond filling prescriptions. Whether it’s taking the lead on prior authorizations, making limited-distribution drugs accessible, helping to ease copay costs or providing adherence services, our team understands cancer patient needs and works with providers to support the prescribed regimen. You and your patients are at the heart of what we do. Our passion is personal.
VCurePrecision (VCP) is a comprehensive real-time decision-support system that combines clinical knowledge and patient data to aid oncologists in ordering diagnostics and then generating optimal patient-specific treatment plans. VCP includes an A.I. inference engine, a clinical knowledge-base containing world-leading precision oncology and standard of care guidance, a fully integrated oncology-specific EMR and a tethered mobile app to capture and action patient compliance and related toxicities.
About GSK: a science-led global healthcare company with a special purpose to help people do more, feel better, live longer. GSK in Oncology: GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
Unlimited Systems equips cancer specialist providers with the industry-leading g4-Centricity revenue cycle platform. Our software simplifies management of complex financial transactions, delivers features valued by Institutional service lines and Freestanding centers, and guides effective and efficient financial workflow at the point of service as well as across the business office.
Walgreens is focused on expert cancer care. Our pharmacists and pharmacy technicians, who have advanced cancer training and expertise, go beyond filling prescriptions. Whether it’s taking the lead on prior authorizations, making limited-distribution drugs accessible, helping to ease copay costs or providing adherence services, our team understands cancer patient needs and works with providers to support the prescribed regimen. You and your patients are at the heart of what we do. Our passion is personal.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.
Today, Merck continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
From our start in Beijing with a handful of scientists and developers, each committed to discovering new oncology treatments, improving access focused on helping patients in China… To today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have no borders. Vision Transform the biopharmaceutical industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world. Mission Build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo. Values All Patients First. Striving to improve the health and well-being of all patients, regardless of location or income Transformational Mindset — Challenging the Status Quo. Embracing innovative ways of doing things at all levels, and stretching our minds to accomplish things that others thought were impossible Sense of Urgency, With Commitment to Quality and Compliance. Maintaining our sense of urgency and agility with a relentless dedication to quality and compliance, with a commitment to continuous improvement Regional and Functional Teamwork. Creating superior teamwork through open, authentic communication and respect for individual differences to enable excellence cross-functionally and around the world Global Capabilities, Local Expertise. Operating at the highest global standards, while understanding and respecting the value and importance of local expertise Effective Non-Hierarchical Decision-Making. Involving inclusively the appropriate people; communicating openly and transparently, listening actively, considering all options; articulating a scientific/logic-based decision; and aligning to support decisions made Individual Growth. Creating an environment, built on diversity and inclusion, in which all employees have an opportunity to grow professionally, affect the world meaningfully, and build lifelong friendships with exceptional people Behavior How we get things done is just as important as what we accomplish — we operate with an unwavering commitment to compliance, ethics, and integrity, and always treat fellow colleagues with respect and dignity
At Heron Therapeutics, our mission is to improve the lives of patients by developing innovative treatments that address important unmet patient needs. We strive to accomplish our goal by applying innovative science and technologies, such as our proprietary Biochronomer® drug delivery technology, to approved pharmacological agents. Our portfolio includes SUSTOL® (granisetron) extended-release injection, CINVANTI® (aprepitant) injectable emulsion, and a drug candidate under evaluation for non-opioid postoperative pain relief.
Jazz Pharmaceuticals plc is a global biopharmaceutical company that develops life-changing medicines for people with limited or no options, so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
As a leader in sleep medicine and with a growing hematology/oncology portfolio, we develop meaningful medicines and bring them to people with unaddressed needs around the world. We seek solutions for rare or complex diseases, and ensure those solutions are available for the often-overlooked patients who need them.
As the field of science has grown so have our R&D capabilities. We actively explore revolutionary drug options ranging from small molecule advancements to biologics, and we work to identify novel compounds within oncology and sleep medicine. This dynamic approach has allowed us to shepherd new medicines to market – from late-stage discovery through clinical development and regulatory approval. All of these advancements are a reflection of our continued investment in an evolving and growing research and development focus.
McKesson is a global leader in healthcare supply chain management, retail pharmacy, healthcare technology, community oncology and specialty care. Our specialty solutions and services help keep your oncology practice strong and independent, allowing you to focus on what matters most – delivering the best care and outcomes for your patients. Through our personalized approach, we deliver solutions that are tailored to the evolving needs of your practice. From practice performance analytics and value-based care resources to managed care contracting, we’ll partner with you to create a sustainable model for growth and profitability. The US Oncology Network helps more than 1,200 independent physicians deliver value-based, integrated care to patients — close to home. Through The Network, independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson. This collaboration allows providers to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.
Myriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor and transforming patient lives worldwide with molecular diagnostics. Myriad discovers and commercializes diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.
Immuno-oncology is a top priority for EMD Serono a business of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The global strategic alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab as a monotherapy, as well as in combination regimens, and is striving to find new ways to treat cancer.
Ipsen Biopharmaceuticals, Inc. is a US affiliate of Ipsen SA, a global biotech company. At Ipsen Biopharmaceuticals, we are focused on developing and providing access to therapies across our core therapeutic areas: oncology, neurology and rare diseases, because our mission is to offer options for patients who suffer from these extremely difficult-to-treat diseases. For more information on Ipsen in North America, please visit www.ipsenus.com.
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
Founded in 1992, MorphoSys is dedicated to bringing breakthrough medicines in oncology to the market to help address unmet needs for patients with B-cell malignancies. By applying our proprietary technologies, MorphoSys has become a world leader in the field of therapeutic antibodies. In 2019, the US headquarters were established in Boston. Connect with MorphoSys to learn more about our company.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.
Sun Pharma is the 4th largest specialty generic pharmaceutical company in the world, providing high-quality, affordable medicines in over 150 countries. Our mission is to enhance people’s lives with innovative and quality generic, branded, and over-the-counter medicines, providing exceptional value in our communities. In the US, Sun Pharma is focused on helping patients in Generics, Dermatology, Oncology, Ophthalmology, and Long-Term Care.
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established world-class clinical development and commercial organizations that work urgently to develop and market innovative cancer treatments in the U.S. Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state-of-the-art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.
Puma Biotechnology, Inc. is a biopharmaceutical company that markets NERLYNX® (neratinib) tablets which is indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy and; In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
